PH Labs Reference Range Summary
PROCEDURE:REFERENCE:
 Collaboration powered by Smartsheet   |   Report Abuse
1
Valid 02/27/21
.
2
Associated Policy:
.
3
Laboratory General Policy
.
4
5
RESPONSIBLE POSITIONS:
.
6
1. Laboratory Workforce
.
7
2. Prisma Health Providers
.
8
9
LABORATORY ADDRESSES:
.
10
Prisma Health Baptist Easley Hospital Laboratory
200 Fleetwood Drive
Easley, SC 29640
Prisma Health Baptist Columbia Hospital Laboratory
Taylor at Marion Street
Columbia, SC 29220
11
Prisma Health Baptist Parkridge Hospital Laboratory
400 Palmetto Health Parkway
Columbia, SC 29212
Prisma Health Greenville Memorial Hospital Laboratory
701 Grove Road
Greenville, SC 29605
12
Prisma Health Greer Memorial Hospital Laboratory
830 S Buncombe Road
Greer, SC 29650
Prisma Health Hillcrest Hospital Laboratory
729 SE Main Street
Simpsonville, SC 29681
13
Kershaw Health Medical Center Laboratory
Haile and Roberts Street
Camden, SC 2902
Prisma Health Laurens County Hospital Laboratory
22725 US-76
Clinton, SC 29325
14
Prisma Health North Greenville Hospital Laboratory
807 N Main Street
Travelers Rest, SC 29690
Prisma Health Oconee Memorial Hospital Laboratory
298 Memorial Drive
Seneca, SC 29672
15
Prisma Health Patewood Hospital Laboratory
175 Patewood Drive
Greenville, SC 29615
Prisma Health Richland Hospital Central Laboratory
14 Richland Medical Park Drive
Columbia, SC 29203
16
Prisma Health Richland Hospital Rapid Laboratory
5 Richland Medical Park Drive
Columbia, SC 29203
Prisma Health Tuomey Hospital Laboratory
129 North Washington Street
Sumter, SC 29150
17
18
PROCEDURE:
REFERENCE:
19
Acetaminophen
10 - 30 ug/mL
20
21
Adenovirus Rapid
Not Detected
22
23
ACT-Kaolin
74 - 152 seconds
24
25
Albumin
SERUM:
0 - 1 Year 2.8 - 4.7 g/dL
1 - 60 Years 3.5 - 5.0 g/dL
> 60 Years 3.4 - 4.8 g/dL

BODY FLUID:
The separation of ascitic fluids into transudates or exudates has been superseded by the division of ascitic fluids into high-gradient or low-gradient fluids as determined by the serum-ascites albumin gradient calculated as (serum albumin) - (ascitic fluid albumin). The gradient is a reflection of the hydrostatic pressure in the portal circulation. Gradients >/=1.1 g/dL are considered high. Specimens of serum and fluid should be drawn the same day. High Values may be seen in: Cirrhosis, Fulminant hepatic failure, Fatty liver, Alcoholic hepatitis, Portal vein thrombosis, Veno-Occlusive disease; Low Values may be seen in Peritoneal carcinomatosis, Tuberculosis, Pancreatic, Connective tissue disease, Nephrotic syndrome, Biliary (without cirrhosis).

Pleural Fluid: Serum Albumin Level - Pleural Fluid Albumin Level </=1.2 g/dL is predictive of an exudate.
26
27
Alcohol, plasma (Medical Only)
< 10 mg/dL
28
29
Alkaline Phosphatase
Female:
0 - 14 Days 90 - 273 IU/L
15 Days - 11 Months 134 - 518 IU/L
1 - 9 Years 156 - 369 IU/L
10 - 12 Years 141 - 460 IU/L
13 - 14 Years 62 - 280 IU/L
15 - 16 Years 54 -128 IU/L
17 - 19 Years 48 - 95 IU/L
>/= 20 Years 40 - 150 IU/L

Male:
0 - 14 Days 90 - 273 IU/L
15 Days - 11 Months 134 - 518 IU/L
1 - 9 Years 156 - 369 IU/L
10 - 12 Years 141 - 460 IU/L
13 - 14 Years 127 - 517 IU/L
15 - 16 Years 89 - 365 IU/L
17 - 19 Years 59 - 164 IU/L
>/= 20 Years 40 - 150 IU/L
30
31
Alkaline Phosphatase, Fractionated
If total Alkaline Phosphatase is elevated and labile fraction exceeds 70%- consistent with bone origin.
32
33
Allergens IgE - Except Peanut Components
< 0.35 kU/L

Interpretive Data:
Less than 0.10 kU/L - Normal: No significant level detected
0.10 - 0.34 kU/L - For Specialists use only: Clinical relevance undetermined
0.35 - 0.70 kU/L - Low: Indicative of ongoing sensitization
0.71 - 3.50 kU/L - Moderate: Indicative of stronger ongoing sensitization
3.51 - 17.50 kU/L - High: Indicative of high level sensitization
17.51 kU/L or Greater - Very High: Indicative of very high level sensitization
34
35
Allergens IgE - Peanut Components
< 0.10 kU/L

Interpretive Data:
Any detectable level (>/= 0.1 kU/L) of Specific IgE for Peanut Components may be significant.
Ara h 1, 2, 3, and 6 are the peanut proteins most linked to systemic allergic reactions, including anaphylaxis. If any one of these four components is positive, the patient has a high risk of systemic allergic reaction when exposed to peanuts, regardless of the whole peanut allergen result.
Reactivity to Ara h 9 and non-reactivity to Ara h 1,2,3 and 6 indicates a variable risk of systemic allergic reaction including anaphylaxis.
Reactivity to Ara h 8 and Profilin and non-reactivity to Ara h 1,2,3 and 6 indicates a lower risk of a systemic allergic reaction. Reactivity to CCD and non-reactive to Ara h 1,2,3 and 6 indicates lowest risk of a systemic allergic reaction.
36
37
Alpha 1 Antitrypsin
90 - 200 mg/dL
38
39
Alpha Fetoprotein Tumor Marker
< 8.79 ng/mL
40
41
ALT (SGPT)
Female:
0 - 11 Months 5 - 33 IU/L
1 - 12 Years 9 - 25 IU/L
13 - 19 Years 8 - 22 IU/L
>/= 20 Years < 55 IU/L

Male:
0 - 11 Months 5 - 33 IU/L
1 - 12 Years 9 - 25 IU/L
13 - 19 Years 9 - 24 IU/L
>/= 20 Years < 55IU/L
42
43
Amikacin
TROUGH:
0 - 2 Months < 5.1 ug/mL
>/= 3 Months 4.0 - 8.0 ug/mL

PEAK:
25.0 - 35.0 ug/mL

RANDOM:
8.0 - 25.0 ug/mL
44
45
Ammonia, Plasma
18 - 72 umol/L
46
47
Amnisure
Negative
48
49
Amylase
SERUM:
0 - 27 Days 5 - 65 IU/L
28 Days - 70 Years 25 - 125 IU/L
>/= 71 Years 20 - 160 IU/L

URINE:
Random: < 651 IU/L
Timed: 24 - 408 IU/24 hrs

BODY FLUID:
Interpretive Data:
Peritoneal: Elevated at very high concentrations in pancreatitis. At least several-fold times higher in fluid of pancreatic origin compared to simultaneous values in serum, even in cases of acute pancreatitis. Elevated in pancreatic injury.
Pleural Fluid: May be high due to contamination with salivary secretions and food in suspected esophageal rupture.
50
51
Anion Gap
6 - 16 mmol/L
52
53
Anti-Streptolysin O (ASO)
0 - 3 Years: < 100 U/mL
4 - 17 Years: < 251 U/mL
>/= 18 Years: < 200 U/mL
54
55
Anti-Thrombin III Assay (ATIII)
80 - 120 %
56
57
APT Fetal Hemoglobin
No fetal hemoglobin
58
59
AST (SGOT)
0-14 Days: 23-186 IU/L
15 Days - 11 Months: 23-83 IU/L
>/=1 Year: 5-34 IU/L
60
61
Beta-2 Glycoprotein Antibodies IgG
< 7.0 U/mL

Interpretive Data:
< 7.0 Normal
7.0-10.0 Equivocal - Recommend to retest the patient after 4-6 weeks.
> 10.0 Positive

The expected value in the normal population is negative. However, up to 3% of apparently healthy, asymptomatic individuals may have increased levels of B2-Glycoprotein I antibodies. Anti-B2 Glycoprotein I antibodies may be present in the so called antiphospholipid syndrome, often appearing in conjunction with SLE, and sometimes occurring without symptoms of SLE. Clinical manifestations can be thrombosis, recurrent pregnancy loss, thrombocytopenia, hemolytic anemia, and other features such as livedo reticularis, migraines, epilepsy, and others.
A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
Expected values may vary on the population tested.
62
63
Beta-2 Glycoprotein Antibodies IgM
< 7.0 U/mL

Interpretive Data:
< 7.0 Normal
7.0-10.0 Equivocal - Recommend to retest the patient after 4-6 weeks.
> 10.0 Positive

The expected value in the normal population is negative. However, up to 3% of apparently healthy, asymptomatic individuals may have increased levels of B2-Glycoprotein I antibodies. Anti-B2 Glycoprotein I antibodies may be present in the so called antiphospholipid syndrome, often appearing in conjunction with SLE, and sometimes occurring without symptoms of SLE. Clinical manifestations can be thrombosis, recurrent pregnancy loss, thrombocytopenia, hemolytic anemia, and other features such as livedo reticularis, migraines, epilepsy, and others.
A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
Expected values may vary on the population tested.

Rheumatoid factor (RF) can interfere with the determination of IgM anti B2 Glycoprotein I antibodies.
64
65
Beta HCG, Quantitative
Pregnancy:
Negative: </= 5 mIU/mL
Inconclusive: > 5 - < 25 mIU/mL
Positive: >/= 25 mIU/mL
Rare false positives have been reported. Positive results should be confirmed with a urine specimen prior to aggressive therapy.

Weeks Post Last Menstrual Period: Approx Total B-hCG Range (mIU/mL)
1-10 Weeks: <1.20 - 231,000
11-15 Weeks: 16,996 - 234,990
16-22 Weeks: 6,860 - 50,064
23-40 Weeks: 1,583 - 49,413

The ARCHITECT Total B-hCG assay is cleared for use in the early detection of pregnancy only. It is not approved for any other uses such as tumor marker screening, tumor marker monitoring, etc. and it should not be performed for any other uses.
66
67
Beta-Hydroxybutyric Acid
0.0 - 0.5 mmol/L

0.6-1.5 mmol/L w/Glucose >/=300 mg/dL
Potential for development of problem requiring medical intervention
>1.5 mmol/L w/Glucose >/=300 mg/dL
May indicate the risk of developing diabetic ketoacidosis (DKA)
68
69
Bilirubin, Direct
0 - 14 Days 0.3 - 0.7 mg/dL
>/= 15 Days 0.0 - 0.5 mg/dL
70
71
Bilirubin, Indirect
0 - 14 Days 0.1 - 9.9 mg/dL
>/= 15 Days 0.0 - 1.2 mg/dL
72
73
Bilirubin, Total
SERUM:
0 - 23 Hours < 6.0 mg/dL
1 - 14 Days 0.1 - 10.3 mg/dL
>/= 15 Days 0.1 - 1.2 mg/dL

BODY FLUID:
Interpretive Data:
Peritoneal: Leakage from biliary ducts should result in fluid levels of bilirubin several -fold higher in the fluid than in serum from the patient. High Bilirubin concentration is presumptive evidence for bile leakage.
74
75
Blood Culture ID by PCR
Not Detected
76
77
Bordetella pertussis DNA
Negative
78
79
Borrelia burgdorferi Ab Total (Lyme)
Negative
80
81
Brain-Type Natriuretic Peptide (BNP)
0 Days - 11 Months < 24 pg/mL
1 Year - 5 Years < 30 pg/mL
6 Years - 10 Years < 15 pg/mL
11 Years - 14 Years < 21 pg/mL
15 Years - 20 Years < 20 pg/mL
>/=21 Years < 100 pg/mL
82
83
Calcium
SERUM:
0 - 11 Months 8.5 - 11.0 mg/dL
1 - 17 Years 9.0 - 10.5 mg/dL
>/= 18 Years 8.5 - 10.4 mg/dL

URINE:
Random:
Male: 0.9 - 37.9 mg/dL
Female: 0.5 - 35.7 mg/dL

Timed:
CA Free Diet 5 - 40 mg/24hr
Low to Average Intake 50 - 150 mg/24hr
Average Intake 100 - 300 mg/24hr

0 - 11 Years: 2.0 - 4.0 mg/kg/24hr
>12 Years: 1.4 - 4.3 mg/kg/24hr
84
85
Calcium/Creatinine Ratio, Urine
Male: < 0.25 mgca/mgcr
Female: < 0.33 mgca/mgcr
86
87
Calcium, Ionized
WHOLE BLOOD: (Upstate)
1.20 - 1.30 mmol/L

PLASMA: (Midlands)
1.09 - 1.30 mmol/L
88
89
Cancer Antigen 125 (CA 125)
< 35.1 U/mL
90
91
Cancer Antigen 15-3 (CA 15-3)
< 31.4 U/mL
92
93
Carbamazepine (Tegretol)
4.0 - 12.0 ug/mL
94
95
Carbapenemase by PCR Screen/Isolate
Not Detected
96
97
Carcinoembryonic Antigen (CEA)
< 5.1 ng/mL
98
99
Cardiolipin Antibody IgA
<14.0 APL U/mL

Interpretive Data:
< 14.0 Negative
14.0-20.0 Equivocal - Recommend to retest the patient after 4-6 weeks.
> 20.0 Positive

Antibody prevalence in autoimmune patients varies widely depending on disease area. The proportion of sera from a normal population found positive for the Cardiolipin IgA covered by the EliA Cardiolipin IgA test is below 5%, increasing with age, and men tend to show higher values. Expected values may vary depending on the population tested.
A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
100
101
Cardiolipin Antibody IgG
< 10.0 GPL U/mL

Interpretive Data:
< 10.0 Negative
10.0-40.0 Weak Positive - Recommend to retest the patient after 8-12 weeks.
> 40.0 Positive

The expected value in the normal population is negative. However, low percentages (up to 5%) of apparently healthy, asymptomatic individuals have been reported to be positive for ACA. Cardiolipin antibodies show the following prevalences in APS:
Primary APS: ACA IgG 81%, ACA IgM 40%, ACA IgA 24%
Secondary APS: ACA IgG 85%, ACA IgM 65%, ACA IgA 10%.
A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
102
103
Cardiolipin Antibody IgM
< 10.0 MPL U/mL

Interpretive Data:
< 10.0 Negative
10.0-40.0 Weak Positive - Recommend to retest the patient after 8-12 weeks.
> 40.0 Positive

The expected value in the normal population is negative. However, low percentages (up to 5%) of apparently healthy, asymptomatic individuals have been reported to be positive for ACA. Cardiolipin antibodies show the following prevalences in APS:
Primary APS: ACA IgG 81%, ACA IgM 40%, ACA IgA 24%
Secondary APS: ACA IgG 85%, ACA IgM 65%, ACA IgA 10%
A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
104
105
-CD4 Level/ T&B Cell Enumeration Panel (CD3, CD4, CD8, CD19, CD16/56) / T Helper/Suppressor, Whole Blood(CD3, CD4, CD8)
Midlands:
106
CD3 (T Cells), Whole Blood
0 - 2 Months: 53.0 - 84.0 %
3 - 5 Months: 51.0 - 77.0 %
6 - 11 Months: 49.0 - 76.0 %
12 - 23 Months: 53.0 - 75.0 %
2 - 5 Years: 56.0 - 75.0 %
6 - 11 Years: 60.0 - 76.0 %
12 - 17 Years: 56.0 - 84.0 %
>/= 18 Years: 58.0 - 84.0 %
107
CD3 Absolute Count, Whole Blood
0 - 2 Months 2500 - 5500 Cells/uL
3 - 5 Months 2500 - 5600 Cells/uL
6 - 11 Months 1900 - 5900 Cells/uL
12 - 23 Months 2100 - 6200 Cells/uL
2 - 5 Years 1400 - 3700 Cells/uL
6 - 11 Years 1200 - 2600 Cells/uL
12 - 17 Years 1000 - 2200 Cells/uL
>/= 18 Years 856 - 2237 Cells/uL
108
CD4 (Helper T Cells), Whole Blood
0 - 2 Months 35.0 - 64.0 %
3 - 5 Months 35.0 - 56.0 %
6 - 11 Months 31.0 - 56.0 %
12 - 23 Months 32.0 - 51.0 %
2 - 5 Years 28.0 - 47.0 %
6 - 11 Years 31.0 - 47.0 %
12 - 17 Years 31.0 - 52.0 %
>/= 18 Years 33.6 - 64.8 %
109
CD4 Absolute Count, Whole Blood
0 - 2 Months 1600 - 4000 Cells/uL
3 - 5 Months 1800 - 4000 Cells/uL
6 - 11 Months 1400 - 4300 Cells/uL
12 - 23 Months 1300 - 3400 Cells/uL
2 - 5 Years 700 - 2200 Cells/uL
6 - 11 Years 650 - 1500 Cells/uL
12 - 17 Years 530 - 1300 Cells/uL
>/= 18 Years 518 - 1472 Cells/uL
110
CD8 (Suppressor T Cells), Whole Blood
0 - 2 Months 12.0 - 28.0 %
3 - 5 Months 12.0 - 23.0 %
6 - 11 Months 12.0 - 24.0 %
12 - 23 Months 14.0 - 30.0 %
2 - 5 Years 16.0 - 30.0 %
6 - 17 Years 18.0 - 35.0 %
>/= 18 Years 13.0 - 37.6 %
111
CD8 Absolute Count, Whole Blood
0 - 2 Months 560 - 1700 Cells/uL
3 - 5 Months 590 - 1600 Cells/uL
6 - 11 Months 500 - 1700 Cells/uL
12 - 23 Months 620 - 2000 Cells/uL
2 - 5 Years 490 - 1300 Cells/uL
6 - 11 Years 370 - 1100 Cells/uL
12 - 17 Years 330 - 920 Cells/uL
>/= 18 Years 205 - 924 Cells/uL
112
CD16/56 NK Cells, Whole Blood
0 - 2 Months 4.0 - 18.0 %
3 - 5 Months 3.0 - 14.0 %
6 - 11 Months 3.0 - 15.0 %
2 - 11 Years 4.0 - 17.0 %
12 - 17 Years 3.0 - 22.0 %
>/= 18 Years 4.3 - 26.6 %
113
CD16/56 Absolute Count, Whole Blood
0 - 2 Months 170 - 1100 Cells/uL
3 - 5 Months 170 - 830 Cells/uL
6 - 11 Months 160 - 950 Cells/uL
12 - 23 Months 180 - 920 Cells/uL
2 - 5 Years 130 - 720 Cells/uL
6 - 11 Years 100 - 480 Cells/uL
12 - 17 Years 70 - 480 Cells/uL
>/= 18 Years 74 - 562 Cells/uL
114
CD19 % (B cells), Whole Blood
0 - 2 Months 6.0 - 32.0 %
3 - 5 Months 11.0 - 41.0 %
6 - 11 Months 14.0 - 37.0 %
12 - 23 Months 16.0 - 35.0 %
2 - 5 Years 14.0 - 33.0 %
6 - 11 Years 13.0 - 27.0 %
12 - 17 Years 6.0 - 23.0 %
>/= 18 Years 5.7 - 24.9 %
115
CD19 Absolute Count, Whole Blood
0 - 2 Months 300 - 2000 Cells/uL
3 - 5 Months 430 - 3000 Cells/uL
6 - 11 Months 610 - 2600 Cells/uL
12 - 23 Months 720 - 2600 Cells/uL
2 - 5 Years 390 - 1400 Cells/uL
6 - 11 Years 270 - 860 Cells/uL
12 - 17 Years 110 - 570 Cells/uL
>/= 18 Years 87 - 507 Cells/uL
116
117
Cell Count, Fluid
CSF:
Nucleated Cells:
0 - 1 Year: 0-22 Cells/uL
1 - 12 Years: 0 - 7 Cells/uL
> 12 Years: 0 - 5 Cells/uL

RBCs: 0 - 2 Cells/uL

BODY FLUID:
Nucleated Cells:
Synovial Fluids: 0-150 mm3
All Other Fluids: 0-500 mm3
118
119
Chlamydia trachomatis, NAAT
Negative
120
121
Chloride
SERUM:
0 - 29 Days: 98 - 113 mmol/L
>/= 30 Days: 98 - 107 mmol/L

URINE:
Random: No Reference Ranges Established

Timed: Varies significantly with hydration and chloride intake.
0 - 27 Days: No Reference Ranges Established
28 Days - 23 Months: 2 - 10 mmol/24 hrs
2 - 17 Years: 15 - 40 mmol/24 hrs
>/= 18 Years: 110 - 250 mmol/24 hrs
122
123
Chloride, Sweat
0 - 29 mmol/L

Interpretive Data:
</= 29 mmol/L - CF unlikely
30-59 mmol/L - Intermediate range, needs further study to establish or rule out a CF diagnosis.
>/= 60 mmol/L - Indicative of CF for individuals presenting with a positive newborn screen, clinical features consistent with CF, or a positive family history.
124
125
CKMB
Male: < 7.3 ng/mL
Female: < 3.5 ng/mL
126
127
Clostridium Difficile Toxin B gene by PCR
Negative
128
129
CO2
0 - 27 Days: 15 - 22 mmol/L
28 Days - 11 Months: 20 - 28 mmol/L
>/= 1 Year: 20 - 30 mmol/L
130
131
Complement, C-3
0 - 11 Months: 50 - 160 mg/dL
1 - 13 Years: 80 - 173 mg/dL
>/= 14 Years: 82 - 193 mg/dL
132
133
Complement, C-4
0 - 11 Months: 7 - 30 mg/dL
1 - 13 Years: 13 - 46 mg/dL
>/= 14 Years: 15 - 57 mg/dL
134
135
-Complete Blood Count (CBC):
.
136
WBC
Male:
0 - 14 Days 8.0 - 15.4 K/uL
15 - 30 Days 7.8 - 15.9 K/uL
31 - 60 Days 8.1 - 15.0 K/uL
2 - 5 Months 6.5 - 13.3 K/uL
6 - 23 Months 6.0 - 13.4 K/uL
2 - 5 Years 5.1 - 13.4 K/uL
6 - 11 Years 4.3 - 11.0 K/uL
12 - 17 Years 3.8 - 9.8 K/uL
>/= 18 Years 4.2 - 9.1 K/uL

Female:
0 - 14 Days 8.2 - 14.6 K/uL
15 - 30 Days 8.4 - 14.4 K/uL
31 - 60 Days 7.1 - 14.7 K/uL
2 - 5 Months 6.0 - 13.3 K/uL
6 - 23 Months 6.5 - 13.0 K/uL
2 - 5 Years 4.9 - 13.2 K/uL
6 - 11 Years 4.3 - 11.4 K/uL
12 - 17 Years 4.2 - 9.4 K/uL
>/=18 Years 4.0 - 10.0 K/uL
137
RBC
Male:
0 - 14 Days: 4.10 - 5.55 M/uL
15 - 30 Days: 3.16 - 4.63 M/uL
31 - 60 Days: 3.02 - 4.22 M/uL
2 - 5 Months: 3.43 - 4.80 M/uL
6 - 23 Months: 4.03 - 5.07 M/uL
2 - 5 Years: 3.89 - 4.97 M/uL
6 - 11 Years: 3.96 - 5.03 M/uL
12 - 17 Years: 4.03 - 5.29 M/uL
>/= 18 Years: 4.63 - 6.08 M/uL

Female:
0 - 14 Days: 4.12 - 5.74 M/uL
15 - 30 Days: 3.32 - 4.80 M/uL
31 - 60 Days: 2.93 - 3.87 M/uL
2 - 5 Months: 3.45 - 4.75 M/uL
6 - 23 Months: 3.97 - 5.01 M/uL
2 - 5 Years: 3.84 - 4.92 M/uL
6 - 11 Years: 3.90 - 4.96 M/uL
12 - 17 Years: 3.93 - 4.90 M/uL
>/= 18 Years: 3.93 - 5.22 M/uL
138
HGB
Male:
0 - 14 Days: 13.9 - 19.1 g/dL
15 - 30 Days: 10.0 - 15.3 g/dL
31 - 60 Days: 8.9 - 12.7 g/dL
2 - 5 Months: 9.6 - 12.4 g/dL
6 - 23 Months: 10.1 - 12.5 g/dL
2 - 5 Years: 10.2 - 12.7 g/dL
6 - 11 Years: 10.7 - 13.4 g/dL
12 - 17 Years: 11.0 - 14.5 g/dL
>/= 18 Years: 13.7 - 17.5 g/dL

Female:
0 - 14 Days: 13.4 - 20.0 g/dL
15 - 30 Days: 10.8 - 14.6 g/dL
31 - 60 Days: 9.2 - 11.4 g/dL
2 - 5 Months: 9.9 - 12.4 g/dL
6 Months - 5 Years: 10.2 - 12.7 g/dL
6 - 11 Years: 10.6 - 13.2 g/dL
12 - 17 Years: 10.8 - 13.3 g/dL
>/= 18 Years: 11.2 - 15.7 g/dL
139
HCT
Male:
0 - 14 Days: 39.8 - 53.6 %
15 - 30 Days: 30.5 - 45.0 %
31 - 60 Days: 26.8 - 37.5 %
2 - 5 Months: 28.6 - 37.2 %
6 - 23 Months:30.8 - 37.8 %
2 - 5 Years: 31.0 - 37.7 %
6 - 11 Years: 32.2 - 39.8 %
12 - 17 Years: 33.9 - 43.5 %
>/= 18 Years: 40.1 - 51.0 %

Female:
0 - 14 Days: 39.6 - 57.2 %
15 - 30 Days: 32.0 - 44.5 %
31 - 60 Days: 27.7 - 35.1 %
2 - 5 Months: 29.5 - 37.1 %
6 - 23 Months:30.9 - 37.9 %
2 - 5 Years: 31.2 - 37.8 %
6 - 11 Years: 32.4 - 39.5 %
12 - 17 Years: 33.4 - 40.4 %
>/= 18 Years: 34.1 - 44.9 %
140
MCV
Male:
0 - 14 Days: 91.3 - 103.1 fL
15 - 30 Days: 89.4 - 99.7 fL
31 - 60 Days: 84.3 - 94.2 fL
2 - 5 Months: 74.1 - 87.5 fL
6 - 23 Months:69.5 - 81.7 fL
2 - 5 Years: 71.3 - 84.0 fL
6 - 11 Years: 74.4 - 86.1 fL
12 - 17 Years: 76.7 - 89.2 fL
>/= 18 Years: 79.0 - 92.2 fL

Female:
0 - 14 Days: 92.7 - 106.4 fL
15 - 30 Days: 90.1 - 103.0 fL
31 - 60 Days: 83.4 - 96.4 fL
2 - 5 Months: 74.8 - 88.3 fL
6 - 23 Months:71.3 - 82.6 fL
2 - 5 Years: 72.3 - 85.0 fL
6 - 11 Years: 75.9 - 87.6 fL
12 - 17 Years: 76.9 - 90.6 fL
>/= 18 Years: 79.4 - 94.8 fL
141
MCH
Male:
0 - 14 Days: 31.3 - 35.6 pg
15 - 30 Days: 29.9 - 34.1 pg
31 - 60 Days: 27.8 - 32.0 pg
2 - 5 Months: 24.4 - 28.9 pg
6 - 23 Months:22.7 - 27.2 pg
2 - 5 Years: 23.7 - 28.3 pg
6 - 11 Years: 24.9 - 29.2 pg
12 - 17 Years: 25.2 - 30.2 pg
>/= 18 Years: 25.7 - 32.2 pg

Female:
0 - 14 Days: 31.1 - 35.9 pg
15 - 30 Days: 30.4 - 35.3 pg
31 - 60 Days: 28.0 - 32.5 pg
2 - 5 Months: 24.4 - 29.5 pg
6 - 23 Months:23.2 - 27.5 pg
2 - 5 Years: 23.7 - 28.6 pg
6 - 11 Years: 24.8 - 29.5 pg
12 - 17 Years: 24.8 - 30.2 pg
>/= 18 Years: 25.6 - 32.2 pg
142
MCHC
Male:
0 - 14 Days: 33.0 - 35.7 g/dL
15 - 30 Days: 32.7 - 35.1 g/dL
31 - 60 Days: 32.3 - 34.8 g/dL
2 - 5 Months: 31.9 - 34.4 g/dL
6 - 23 Months:31.6 - 34.4 g/dL
2 - 5 Years: 32.0 - 34.7 g/dL
6 - 11 Years: 32.2 - 34.9 g/dL
12 - 17 Years: 31.8 - 34.8 g/dL
>/= 18 Years: 32.2 - 36.5 g/dL

Female:
0 - 14 Days: 33.4 - 35.4 g/dL
15 - 30 Days: 33.2 - 35.0 g/dL
31 -60 Days: 32.5 - 34.9 g/dL
2 - 5 Months: 32.1 - 34.4 g/dL
6 - 23 Months:31.9 - 34.2 g/dL
2 - 11 Years: 31.8 - 34.6 g/dL
12 - 17 Years: 31.5 - 34.2 g/dL
>/= 18 Years: 32.2 - 35.3 g/dL
143
RDW-CV
Male:
0 - 14 Days: 14.8 - 17.0 %
15 - 30 Days: 14.3 - 16.8 %
31 - 60 Days: 13.8 - 16.1 %
2 - 5 Months: 12.4 - 15.3 %
6 - 23 Months:12.9 - 15.6 %
2 - 5 Years: 12.5 - 14.9 %
6 - 11 Years: 12.3 - 14.1 %
12 - 17 Years: 12.4 - 14.5 %
>/= 18 Years: 11.6 - 14.4 %

Female:
0 - 14 Days: 14.6 - 17.3 %
15 - 30 Days: 14.4 - 16.2 %
31 - 60 Days: 13.6 - 15.8 %
2 - 5 Months: 12.2 - 14.3 %
6 - 23 Months:12.7 - 15.1 %
2 - 5 Years: 12.4 - 14.9 %
6 - 11 Years: 12.2 - 14.4 %
12 - 17 Years: 12.3 - 14.6 %
>/= 18 Years: 11.7 - 14.4 %
144
RDW-SD
Male:
0 - 14 Days: 51.0 - 61.7 fL
15 - 30 Days: 46.3 - 57.3 fL
31 - 60 Days: 43.9 - 52.8 fL
2 - 5 Months: 35.3 - 45.7 fL
6 - 23 Months:35.3 - 45.7 fL
2 - 5 Years: 35.3 - 42.8 fL
6 - 11 Years: 35.1 - 41.7 fL
12 - 17 Years: 36.7 - 43.8 fL
>/= 18 Years: 35.1 - 43.9 fL

Female:
0 - 14 Days: 51.4 - 65.7 fL
15 - 30 Days: 47.2 - 59.8 fL
31 - 60 Days: 43.0 - 55.0 fL
2 - 5 Months: 35.2 - 45.1 fL
6 - 23 Months:34.9 - 42.4 fL
2 - 5 Years: 34.9 - 42.0 fL
6 - 11 Years: 35.5 - 41.8 fL
12 - 17 Years: 37.1 - 44.2 fL
>/= 18 Years: 36.4 - 46.3 fL
145
MPV
Male:
0 - 14 Days: 10.2 - 11.9 fL
15 - 30 Days: 10.1 - 12.1 fL
31 - 60 Days: 9.2 - 10.8 fL
2 - 5 Months: 8.9 - 10.6 fL
6 - 23 Months:8.7 - 10.5 fL
2 - 5 Years: 9.0 - 10.9 fL
6 - 11 Years: 9.2 - 11.4 fL
12 - 17 Years: 9.6 - 11.8 fL
>/= 18 Years: 9.4 - 12.4 fL

Female:
0 - 14 Days: 10.4 - 12.0 fL
15 - 30 Days: 10.0 - 12.2 fL
31 - 60 Days: 9.4 - 11.1 fL
2 - 5 Months: 9.0 - 10.9 fL
6 - 23 Months: 8.8 - 10.6 fL
2 - 5 Years: 8.9 - 11.0 fL
6 - 11 Years: 9.3 - 11.3 fL
12 - 17 Years: 9.6 - 11.7 fL
>/= 18 Years: 9.4 - 12.3 fL
146
Platelet Count
Male:
0 - 14 Days: 218 - 419 K/uL
15 - 30 Days: 248 - 586 K/uL
31 - 60 Days: 229 - 562 K/uL
2 - 5 Months: 244 - 529 K/uL
6 - 23 Months:206 - 445 K/uL
2 - 5 Years: 202 - 403 K/uL
6 - 11 Years: 206 - 369 K/uL
12 - 17 Years: 175 - 332 K/uL
>/= 18 Years: 163 - 337 K/uL

Female:
0 - 14 Days: 144 - 449 K/uL
15 - 30 Days: 279 - 571 K/uL
31 - 60 Days: 331 - 597 K/uL
2 - 5 Months: 247 - 580 K/uL
6 - 23 Months:214 - 459 K/uL
2 - 5 Years: 189 - 394 K/uL
6 - 11 Years: 199 - 367 K/uL
12 - 17 Years: 194 - 345 K/uL
>/= 18 Years: 182 - 369 K/uL
147
Nucleated RBCs
ABSOLUTE:
0 - 3 Days: 0.1 - 8.3
>/= 4 Days: 0.0 - 0.2

PERCENT:
0 - 3 Days: 0 - 8 %
>/= 4 Days: 0 %
148
-Differential White Count
.
149
Neutrophils, Absolute
Male:
0 - 14 Days: 1.60 - 6.06 K/uL
15 - 30 Days: 1.18 - 5.45 K/uL
31 - 60 Days: 0.83 - 4.23 K/uL
61 - 180 Days:0.97 - 5.45 K/uL
6 - 23 Months:1.19 - 7.21 K/uL
2 - 5 Years: 1.54 - 7.92 K/uL
6 - 11 Years: 1.63 - 7.55 K/uL
12 - 17 Years: 1.54 - 7.04 K/uL
>/= 18 Years: 1.78 - 5.38 K/uL

Female:
0 - 14 Days: 1.73 - 6.75 K/uL
15 - 30 Days: 1.23 - 4.80 K/uL
31 - 60 Days: 1.00 - 4.68 K/uL
61 - 180 Days:1.04 - 7.20 K/uL
6 - 23 Months:1.27 - 7.18 K/uL
2 - 5 Years: 1.60 - 8.29 K/uL
6 - 11 Years: 1.64 - 7.87 K/uL
12 - 17 Years: 1.82 - 7.47 K/uL
>/= 18 Years: 1.56 - 6.13 K/uL
150
Lymphocytes, Absolute
Male
0 - 14 Days: 2.07 - 7.53 K/uL
15 - 30 Days: 2.11 - 8.38 K/uL
31 - 60 Days: 2.47 - 7.95 K/uL
61 - 180 Days: 2.45 - 8.89 K/uL
6 - 23 Months: 1.56 - 7.83 K/uL
2 - 5 Years: 1.13 - 5.52 K/uL
6 - 11 Years: 0.97 - 3.96 K/uL
12 - 17 Years 0.97 - 3.26 K/uL
>/= 18 Years: 1.32 - 3.57 K/uL

Female
0 - 14 Days: 1.75 - 8.00 K/uL
15 - 30 Days: 2.42 - 8.20 K/uL
31 - 60 Days: 2.29 - 9.14 K/uL
61 - 180 Days: 2.14 - 8.99 K/uL
6 - 23 Months: 1.52 - 8.99 K/uL
2 - 5 Years: 1.25 - 5.77 K/uL
6 - 11 Years: 1.16 - 4.28 K/uL
12 - 17 Years: 1.16 - 3.33 K/uL
>/= 18 Years: 1.18 - 3.74 K/uL
151
Monocytes, Absolute
Male:
0 - 14 Days: 0.52 - 1.77 K/uL
15 - 30 Days: 0.28 - 1.38 K/uL
31 - 60 Days: 0.28 - 1.05 K/uL
2 - 5 Months: 0.28 - 1.07 K/uL
6 - 23 Months: 0.25 - 1.15 K/uL
24 - 35 Months: 0.19 - 0.94 K/uL
3 - 5 Years: 0.30 - 0.90 K/uL
6 - 16 Years: 0.20 - 0.80 K/uL
>/= 17 Years: 0.30 - 0.82 K/uL

Female:
0 - 14 Days: 0.57 - 1.72 K/uL
15 - 30 Days: 0.42 - 1.21 K/uL
31 - 60 Days: 0.28 - 1.21 K/uL
2 - 5 Months: 0.24 - 1.17 K/uL
6 - 23 Months: 0.26 - 1.08 K/uL
24 - 35 Months: 0.24 - 0.92 K/uL
3 - 5 Years: 0.30 - 0.90 K/uL
6 - 16 Years: 0.20 - 0.80 K/uL
>/= 17 Years: 0.24 - 0.86 K/uL
152
Eosinophils, Absolute
Male:
0 - 14 Days: 0.12 - 0.66 K/uL
15 - 30 Days: 0.08 - 0.80 K/uL
31 - 60 Days: 0.05 - 0.57 K/uL
2 - 5 Months: 0.03 - 0.61 K/uL
6 - 23 Months: 0.02 - 0.82 K/uL
24 - 35 Months: 0.03 - 0.53 K/uL
3 - 11 Years: 0.00 - 0.50 K/uL
12 - 16 Years: 0.10 - 0.20 K/uL
>/= 17 Years: 0.04 - 0.54 K/uL


Female:
0 - 14 Days: 0.09 - 0.64 K/uL
15 - 30 Days: 0.06 - 0.75 K/uL
31 - 60 Days: 0.04 - 0.63 K/uL
2 - 5 Months: 0.02 - 0.74 K/uL
6 - 23 Months: 0.02 - 0.58 K/uL
24 - 35 Months: 0.03 - 0.46 K/uL
3 - 11 Years: 0.00 - 0.50 K/uL
12- 16 Years: 0.10 - 0.20 K/uL
>/= 17 Years 0.04 - 0.36 K/uL
153
Basophils, Absolute
Male:
0 - 14 Days: 0.02 - 0.11 K/uL
15 - 30 Days: 0.01 - 0.07 K/uL
2 - 35 Months: 0.01 - 0.06 K/uL
3 - 16 Years: 0.00 - 0.10 K/uL
>/= 17 Years: 0.01 - 0.08 K/uL

Female:
0 - 14 Days 0.02 - 0.07 K/uL
15 - 30 Days: 0.01 - 0.06 K/uL
31 - 60 Days: 0.01 - 0.05 K/uL
2 - 5 Months: 0.01 - 0.07 K/uL
6 - 35 Months: 0.01 - 0.06 K/uL
3 - 16 Years: 0.00 - 0.10 K/uL
>/= 17 Years: 0.01 - 0.08 K/uL
154
Immature Granulocytes, Absolute
0.00 - 0.03 K/uL
155
156
Cortisol
0 - 14 Days: 0.5 - 12.3 ug/dL
15 Days - 11 Months: 0.5 - 16.6 ug/dL
1 - 8 Years: 1.7 - 10.8 ug/dL
9 - 13 Years: 2.2 - 12.7 ug/dL
14 - 16 Years: 2.8 - 16.4 ug/dL
17 - 19 Years: 3.5 - 18.3 ug/dL
>/= 20 Years:
Before 10 am 3.7 - 19.4
After 10 am 2.9 - 17.3
157
158
Cortisol Stimulation
> 20 ug/dL
159
160
Cotinine
Negative
161
162
COVID-19 PCR
Negative
163
164
COVID-19 IgG
Negative
165
166
C-peptide
0.78 - 5.19 ng/mL
167
168
C-Reactive Protein (CRP)
INFLAMMATION:
0 - 12 Months: 4.8 - 15.2
1 - 6 Years: 4.7 - 25.3
6 - 11 Years: 4.8 - 11.8
11 - 15 Years: 4.8 - 18.1
15 - 21 Years: 4.6 - 24.2
>/= 21 Years: </= 5.0

HIGH SENSITIVE:
Low Risk: < 1.0 mg/L
Average Risk: 1.0 - 3.0 mg/L
High Risk: 3.1 - 9.9 mg/L
Very High Risk: > 9.9 mg/L
169
170
Creatinine
SERUM:
0 - 14 Days: 0.42-1.05 mg/dL
15 Days - 11 Months:0.31-0.53 mg/dL
1 - 11 Years: 0.39-0.69 mg/dL
12 - 14 Years: 0.57-0.80 mg/dL
15 - 17 Years:
Male :0.65-1.10 mg/dL
Female: 0.59-0.88 mg/dL
>/= 18 Years:
Male: 0.72-1.25 mg/dL
Female: 0.57-1.11 mg/dL

URINE:
Random: No Established Reference Range

Timed/24 Hr:
Male: 950 - 2490 mg/24 hours
Female: 710 - 1650 mg/24 hours

Timed Concentration:
Male: 63 - 166 mg/dL
Female: 47 - 110 mg/dL

Clearance:
Male: 66 - 163 mL/min/1.73 m2
Female: 66 - 165 mL/min/1.73 m2

24 hr Excretion (Output):
0 - 23 Months: 9.0-18.0 mg/kg/24 hr
2 - 12 Years: 18.0-24.0 mg/kg/24 hr
13 - 17 Years:
Male: 27.0-30.0 mg/kg/24 hr
Female: 18.0-24.0 mg/kg/24hr
>/=18 Years:
Male:12.1 - 28.9 mg/kg/24hr
Female:10.7 - 26.0 mg/kg/24hr

BODY FLUID:
Pleural and Peritoneal: Urine extravasation will usually present as a transudate with a high concentration of creatinine and urea and a low concentration of glucose and pH. Peritoneal Fluid creatinine concentration will be markedly elevated (2.0-10.0 mg/dL), with the creatinine to serum creatinine greater than 1.0. In the situation in which fluid aspiration inadvertently consists of urine from the bladder, the urea to creatinine ratio should be much higher than for peritoneal fluid from which urea is more readily absorbed than creatinine. Leakage of urine should be suspected when the fluid has a high creatinine concentration relative to that in serum from a simultaneously collected blood specimen.
171
172
Creatine Phosphokinase (CPK)
Male: 30 - 200 U/L
Female: 29 - 168 U/L
173
174
Cryptococcal Antigen, Blood/CSF
Negative
175
176
Cryptosporidium Antigen
Negative
177
178
Cryptosporidium Stain
Absent
179
180
Crystals, Body Fluid
No crystals identified
181
182
Cyclic Citrullinated Peptide (CCP) AB EliA
0.4 - 6.9 U/mL

Interpretive Data:
0.4-6.9: Negative
7.0-10.0: Equivocal
> 10.0: Positive
183
184
Cyclosporine
Upstate:
100.0 - 200.0 ng/mL

Midlands:
100 - 400 ng/mL

Interpretive Data:
Therapeutic ranges are poorly defined. They are related to clinical protocol, the organ transplanted, time following transplantation, organ function, and coadministration of other drugs. Ranges are also method and specimen dependent.
185
186
Cytomegalovirus (CMV) IgG
Negative
187
188
Cytomegalovirus (CMV) IgM
Negative
189
190
D-Dimer FEU
< 0.50 ug/mL

Interpretive Data:
For Outpatients with a value of less than 0.50 ug/ml FEU and with low to moderate clinical pretest probability, this method is FDA cleared to exclude pulmonary emoblism (PE) and as an aid in the diagnosis of deep venous thrombosis (DVT).
191
192
DHEA Sulfate
Male:
11 Years - 14 Years: 26.0 - 380.0 ug/dL
15 Years - 20 Years: 86.0 - 634.0 ug/dL
21 Years - 24 Years: 238.4 - 539.3 ug/dL
25 Years - 34 Years: 167.9 - 591.9 ug/dL
35 Years - 44 Years: 139.7 - 484.4 ug/dL
45 Years - 54 Years: 136.2 - 447.6 ug/dL
55 Years - 64 Years: 48.6 - 361.8 ug/dL
65 Years - 69 Years: 228.5 - 283.6 ug/dL
>/= 70 Years 34.5 - 568.9 ug/dL

Female:
11 Years - 14 Years: 26.0 - 380.0 ug/dL
15 Years - 20 Years: 50.0 - 459.0 ug/dL
21 Years - 24 Years: 134.2 - 407.4 ug/dL
25 Years - 34 Years: 95.8 - 511.7 ug/dL
35 Years - 44 Years: 74.8 - 410.2 ug/dL
45 Years - 54 Years: 56.2 - 282.9 ug/dL
55 Years - 64 Years: 29.7 - 182.2 ug/dL
65 Years - 69 Years: 33.6 - 78.9 ug/dL
>/= 70 Years 25.9 - 460.2 ug/dL
193
194
Digoxin
0.8 - 2.0 ng/mL
195
196
Dilantin Total (Phenytoin)
Total: 10.0 - 20.0 ug/mL

Free: 1.0 - 2.0 ug/mL

Free %: 10 - 20%
197
198
Dilute Russell Viper Venom (dRVVT)
No evidence of phospholipid inhibitor
199
200
-Drug Screen, Urine
.
201
Alcohol
Negative (cutoff 40 ng/mL)
202
Amphetamines
Negative (cutoff 500 ng/mL)
203
Barbiturates
Negative (cutoff 200 ng/mL)
204
Benzodiazepines
Negative (cutoff 200 ng/mL)
205
Cannabinoids
Negative (cutoff 50 ng/mL)
206
Cocaine Metabolites
Negative (cutoff 150 ng/mL)
207
Codeine
Negative (cutoff 2000 ng/mL)
208
Ecstasy (MDMA)
Negative (cutoff 500 ng/mL)
209
Metamphetamine
Negative (cutoff 500 ng/mL)
210
Methadone
Negative (cutoff 300 ng/mL)
211
Morphine
Negative (cutoff 2000 ng/mL)
212
Opiates
Negative (cutoff 300 ng/mL)
213
Oxycodone
Negative (cutoff 100 ng/mL)
214
Phencyclidine
Negative (cutoff 25 ng/mL)
215
Tramadol
Negative (cutoff 200 ng/mL)
216
Tricyclics
Negative (cutoff 300 ng/mL)
217
Fentanyl
Negative (cutoff 1 ng/mL)
218
219
Epstein Barr Virus (EBV) VCA IgG
Negative
220
221
Epstein Barr Virus (EBV) VCA IgM
Negative
222
223
Erythrocyte Sedimentation Rate (ESR)
ESR PLUS:
Male:
0 - 49 Years: 0-15 mm/hr
50 - 84 Years: 0-20 mm/hr
>/= 85 Years: 0-30 mm/hr

Female:
0 - 49 Years: 0-20 mm/hr
50 - 84 Years: 0-30 mm/hr
>/= 85 Years: 0-42 mm/hr

ISED:
Male:
0 - 11 Months: 0 - 2 mm/hr
1 - 11 Years: 3 - 13 mm/hr
12 - 49 Years: 0 - 15 mm/hr
>/= 50 Years: 0 - 20 mm/hr

Female:
0 - 11 Months: 0 - 2 mm/hr
1 - 11 Years: 3 - 13 mm/hr
12 - 49 Years: 0 - 20 mm/hr
>/= 50 Years: 0 - 30 mm/hr
224
225
Estradiol
Male: 11 - 44 pg/mL

Female:
Pre-pubertal: < 20 pg/mL
Follicular phase: 21-251 pg/mL
Mid-cycle: 38-649 pg/mL
Luteal Phase: 21-312 pg/mL
Postmenopausal: <29 pg/mL
Postmenopausal on HRT: <145 pg/mL
226
227
-Coagulation Factors
.
228
Factor II
70-120 %
229
Factor V
70-120 %
230
Factor VII
55-170 %
231
Factor VIII
60-150 %
232
Factor IX
60-150 %
233
Factor X
70-120 %
234
Factor XI
70-120 %
235
Factor VIII Related Antigen (vWF Antigen)
> 49 %
236
237
Fecal Fat, Qualitative
Negative*

*Small amount of neutral fat is normal.
238
239
Fecal Lactoin
Negative
240
241
Fecal Occult Blood, Immunochemical
Negative
242
243
Ferritin
0 - 4 Days: No reference range established
4 - 14 Days: 100.0 - 717.0 ng/mL
15 - 180 Days: 14.0 - 647.0 ng/mL
6 - 11 Months: 8.0 - 182.0 ng/mL
1 - 4 Years: 5.0 - 100.0 ng/mL
5 - 13 Years: 14.0 - 79.0 ng/mL
14 - 15 Years:
Male: 13.0 - 83.0 ng/mL
Female: 6.0 - 67.0 ng/mL
16 - 19 Years:
Male: 11.0 - 172.0 ng/mL
Female: 6.0 - 67.0 ng/mL
>/= 20 Years:
Male: 22.0 - 275.0 ng/mL
Female: 5.0 - 204.0 ng/mL
244
245
Fetal Fibronectin
Negative
246
247
Fetal Hgb Flow Marker
< 0 %
248
249
Fibrin Degradation Products (FDP)
< 5 ug/mL
250
251
Fibrinogen
240 - 490 mg/dL
252
253
Folate
7.0 - 31.4 ng/mL
254
255
Follicle-Stimulating Hormone (FSH)
Male:
1 - 11 Months: 0.1 - 2.4 mIU/mL
1 - 4 Years: 0.0 - 0.9 mIU/mL
5 - 9 Years: 0.0 - 1.6 mIU/mL
10 - 12 Years: 0.4 - 3.9 mIU/mL
13 - 18 Years: 0.8 - 5.1 mIU/mL
>/= 19 Years: 1.0 - 12.0 mIU/mL

Female:
1 - 11 Months: 0.4 - 10.4 mIU/mL
1 - 8 Years: 0.4 - 5.5 mIU/mL
9 - 10 Years: 0.4 - 4.2 mIU/mL
11 - 18 Years: 0.3 - 7.8 mIU/mL
>/= 18 Years:
Normally Menstruating Females:
Follicular Phase: 3.0 - 8.1 mIU/mL
Mid-Cycle: 2.6 - 16.7 mIU/mL
Luteal: 1.4 - 5.5 mIU/mL
Post Menopausal: 26.8 - 133.4 mIU/mL
256
257
G-6-PD Screen
Normal
258
259
Gamma Glutamyltransferase (GGT)
Male: 12 - 64 IU/L
Female: 9 - 36 IU/L
260
261
Gentamicin
TROUGH:
0 - 2 Months < 1.1 ug/mL
>/= 3 Months < 2.0 ug/mL

PEAK:
5.0 - 10.0 ug/mL

RANDOM:
2.0 - 10.0 ug/mL
262
263
GI Panel by PCR
Not Detected
264
265
Giardia Antigen
Negative
266
267
Glomerular Filtration Rate (GFR)
>/= 2 Years: > 59 mL/min/1.73 m2*

*Interpret with caution, quantification of eGFR values below 60 mL/min/1.73 sq meter has more clinical implications for classification of kidney function than values above this level. GFR and GFRA are calculated using the CKD-EPI equation for >18 Years and Bedside Schwartz for 2-18 Years.
268
269
Gliadin Deamidated Peptide Ab, IgA EliA
< 7.0 U/mL

Interpretive Data:
Negative 0.1-6.9 U/mL
Equivocal 7.0-10.0 U/mL
Positive >10.0 U/mL
270
271
Gliadin Deamidated Peptide Ab, IgG EliA
< 7.0 U/mL

Interpretive Data:
Negative 0.4-6.9 U/mL
Equivocal 7.0-10.0 U/mL
Positive >10.0 U/mL
272
273
Glomerular Basement Membrane Antibody (GBM) EliA
< 7.0 U/mL

Normal < 7.0 U/mL
Equivocal 7.0-10.0 U/mL
Positive > 10.0 U/mL
274
275
-Glucose
.
276
Glucose, Serum
NICU: 51 - 60 mg/dL

0 - 23 Hours: 40 - 60 mg/dL
1 Day - 11 Months: 54 - 80 mg/dL
>/= 1 Year: 70 - 99 mg/dL

Interpretive Data:
Fasting Glucose:
Impaired Fasting 100 - 125 mg/dL
Diagnostic of Diabetes Mellitus >/= 126 mg/dL

Random Glucose:
Reference: 70 - 139 mg/dL
Diagnostic of Diabetes Mellitus >/= 200 mg/dL
277
Glucose, Post Prandial:
< 180 for Non-Pregnant Adults with Diabetes
</= 120 for Women with GDM
278
Glucose, 2 Hour Tolerance (non-gestational)
Fasting: 70 - 99 mg/dL
Interpretive Data:
70-99 Normal
100 - 125 Increased risk for Diabetes
>/= 126 Provisional Diagnosis of Diabetes

2 Hour: 70 - 139 mg/dL
Interpretive Data:
70-139 Normal
140-199 Increased risk for Diabetes
>/= 200 Provisional Diagnosis of Diabetes
279
Glucose, Gestational Screen
70 - 139 mg/dL
280
Glucose, Gestational Tolerance
The diagnosis of Gestational Diabetes Mellitus is made if at least two of the following four plasma glucose levels are met or exceeded:
Fasting: < 95 mg/dL
1 Hour: < 180 mg/dL
2 Hour: < 155 mg/dL
3 Hour: < 140 mg/dL
281
Glucose, CSF
0-10 Years: 60-80 mg/dL
>/= 11 Years: 40-70 mg/dL
282
Glucose, Pleural Fluid
< 60 mg/dL is suggestive of an empyema or parapneumonic effusion.
283
Glucose, Estimated Average
Refer to Glucose
284
285
Group B Strep by Rapid PCR
Negative
286
287
Haptoglobin
0 - 14 Days: < 10 mg/dL
15 Days - 23 Months: 7 - 221 mg/dL
1 - 17 Years: 7 - 179 mg/dL
18 - 60 Years:
Male: 14 - 258 mg/dL
Female: 35 - 250 mg/dL
>/= 61 Years:
Male: 40 - 268 mg/dL
Female: 63 - 273 mg/dL
288
289
Hemoglobin A1C
< 5.7 %

Interpretive Data:
5.7 – 6.4% At Risk for Diabetes Mellitus

If HbA1C results are not consistent with blood glucose monitoring results, interference should be considered.

>/= 6.5% Diagnostic for Diabetes Mellitus.
For monitoring diabetic patients, it is recommended that glycemic goals are individualized following current American Diabetes Association (ADA) Standards of Care recommendations.
290
291
Hemoglobin Electrophoresis
Hgb A1: 96.0 - 98.0 %
Hgb A2: 1.5 - 4.0 %
Hgb S: 0.0 %
Hgb C: 0.0 %
Other Hgb 1: 0.0 %
Hgb F:
0 - 6 Days: 77.0 - 97.9 %
7 - 14 Days: 79.6 - 91.4 %
15 - 45 Days: 59.8 - 89.6 %
46 Days - 2 Months: 23.9 - 67.2 %
3 - 5 Months: 4.4 - 27.5 %
6 - 8 Months: 1.5 - 27.8 %
9 - 14 Months: 0.4 - 8.4 %
15 - 23 Months: 0.1 - 4.9 %
2 - 5 Years: 0.0 - 3.7 %
6 - 17 Years: 0.0 - 1.3 %
>/= 18 Years: 0.0 - 0.0 %
292
293
Hemosiderin Laden Macrophage
Absent
294
295
Hepatitis A Antibody IgM
Non-Reactive
296
297
Hepatitis B Surface Antibody
< 8.00 mIU/mL: Non-Reactive - Individual is considered not immune to HBV infection.

>/= 8.00 to < 12.00 mIU/mL: Gray Zone - The immune status of the individual should be further assessed by considering other factors, such as clinical status, follow-up testing, associated risk factors, and the use of additional diagnostic information.

>/= 12.00 mIU/mL: Reactive - Individual is considered immune to HBV infection.
298
299
Hepatitis B Surface Antigen
Non-Reactive
300
301
Hepatitis B Core IgM
Non-Reactive
302
303
Hepatitis B Core Total Ab
Non-Reactive
304
305
Hepatitis C Antibody
Non-Reactive
306
307
Hepatitis C RNA by PCR, Quant
Not Detected
308
309
Herpes Simplex Virus (HSV), DNA by PCR
Not Detected
310
311
Herpes Simplex (HSV) Type 1 IgG
Negative
312
313
Herpes Simplex (HSV) Type 2 IgG
Negative
314
315
Herpes Simplex (HSV) I & II IgM
Negative
316
317
HIV Ag w/HIV1 & 2 Antibodies Screen
Non-Reactive
318
319
HIV Antibody
Non-Reactive
320
321
HIV Antigen
Non-Reactive
322
323
HIV-1 Viral Load RNA by PCR, Quantitative
Less than Limit of Dectection
324
325
Homocystine
Male: 5.5 - 16.2 umol/L
Female: 4.4 - 13.6 umol/L
326
327
Human Papillomavirus (HPV)
Negative
328
329
Immature Platelet Fraction (IPF)
1.1 - 6.1 %
330
331
Immunoglobulin A (IgA)
0 - 11 Months: 1 - 29 mg/dL
1 - 2 Years: 4 - 90 mg/dL
3 - 5 Years: 26 - 147 mg/dL
6 - 13 Years: 47 - 221 mg/dL
14 - 18 Years: 53 - 287 mg/dL
19 - 59 Years:
Male: 63 - 484 mg/dL
Female: 65 - 421 mg/dL
>/= 60 Years:
Male: 101 - 645 mg/dL
Female: 69 - 517 mg/dL
332
333
Immunoglobulin E (IgE)
0 - 5 Months: <14 kU/L
6 - 11 Months: < 35 kU/L
1 - 2 Years: < 98 kU/L
3 - 3 Years: < 200 kU/L
4 - 6 Years: < 308 kU/L
7 - 8 Years: < 404 kU/L
9 - 12 Years: < 697 kU/L
13 - 15 Years: < 630 kU/L
16 - 17 Years: < 538 kU/L
>/=18 Years: < 215 kU/L
334
335
Immunoglobulin G (IgG)
0 - 14 Days: 320 - 1407 mg/dL
15 Days - 11 Months: 109 - 702 mg/dL
1 - 3 Years: 316 - 1148 mg/dL
4 - 9 Years: 542 - 1358 mg/dL
10 - 19 Years: 658 - 1534 mg/dL
>/=20 Years:
Male: 540 - 1822 mg/dL
Female: 552 - 1631 mg/dL
336
337
Immunoglobulin M (IgM)
0 - 14 Days: 5 - 35 mg/dL
15 Days - 2 Months 12 - 71 mg/dL
3 - 11 Months: 16 - 86 mg/dL
1 - 18 Years:
Male: 39 - 151 mg/dL
Female: 48 - 186 mg/dL
>/= 19 Years:
Male: 22 - 240 mg/dL
Female: 33 - 293 mg/dL
338
339
India Ink Prep
Negative
340
341
Influenza A/B PCR
Negative
342
343
Influenzae A & B Antigen Screen
Negative
344
345
Insulin, Fasting
3.0 - 19.0 uU/mL
346
347
Iron
0 - 13 Years 16 - 128 ug/dL
>/= 14 Years:
Male: 65 - 175 ug/dL
Female: 50 - 170 ug/dL
348
349
Iron Binding Capacity (TIBC), Calculated
0 - 62 Days: 130 - 280 ug/dL
63 Days - 11 Months: 134 - 405 ug/dL
1 - 59 Years:
Male: 218 - 455 ug/dL
Female: 225 - 478 ug/dL
>/= 60 Years:
Male: 204 - 569 ug/dL
Female: 216 - 450 ug/dL
350
351
Lactate Dehydrogenase (LDH)
SERUM:
0 - 14 Days: 309 - 1222 IU/L
15 Days - 11 Months: 163 - 452 IU/L
1 - 9 Years: 192 - 321 IU/L
10 - 14 Years:
Male: 170 - 283 IU/L
Female: 157 - 272 IU/L
15 - 18 Years: 130 - 250 IU/L
>/= 19 Years: 125 - 220 IU/L

BODY FLUID:
Interpretive Data:
Ratio of Pleural Fluid LDH to a simultaneously collected Serum Protein >0.6 is predictive of an exudate.
352
353
Lactic Acid
PLASMA:
0.5 - 2.2 mmol/L

CSF:
0.6 - 2.2 mmol/L
354
355
Legionella Antigen, Urine
Negative
356
357
Levetracitam (Keppra)
5.0 - 45.0 ug/mL
358
359
Lipase
0 - 18 Years: 0 - 39 IU/L
>/= 19 Years: 8 - 78 IU/L
360
361
Lipid Laden Macrophage
Negative
362
363
-Lipid Panel
Refer to ACC/AHA Clinical Practice Guidelines
364
Cholesterol
0 - 14 Days: 42 - 125 mg/dL
15 Days - 11 Months: 64 - 237 mg/dL
1 - 9 Years: 112 - 208 mg/dL
10 - 19 Years: < 170 mg/dL
>/= 20 Years: < 200 mg/dL
365
Cholesterol/HDL Ratio
< 3.5
366
HDL
0 - 15 Days: 15 - 42 mg/dL
15 Days - 1 Year: 12 - 71 mg/dL
1 - 10 Years: 32 - 73 mg/dL
10 - 19 Years: > 45 mg/dL
>/= 20 Years: > 59 mg/dL
367
LDL
0 - 11 Months: 13 - 173 mg/dL
1 - 9 Years: 47 - 128 mg/dL
10 - 19 Years: < 110 mg/dL
>/=20 Years: <130 mg/dL
368
Non-HDL Cholesterol
0 - 11 Months: 28 - 202 mg/dL
1 - 9 Years: 69 - 166 mg/dL
10 - 19 Years: < 120 mg/dL
>/= 20 Years: < 130 mg/dL
369
Triglycerides
0 - 9 Years: <75 mg/dL
10 - 19 Years: < 90 mg/dL
>/= 20 Years: < 150 mg/dL
370
VLDL
< 40 mg/dL
371
372
Lithium
0.6 - 1.2 mmol/L
373
374
Low Molecular Weight Heparin (LMWH)
Once daily dosing: 1.00 - 2.00 IU/mL
Twice daily dosing: 0.60 - 1.00 IU/mL
Prophylactic range: 0.20 - 0.50 IU/mL
375
376
Luteinizing Hormone (LH)
Female:
4 Days - 2 Months: 0.0 - 2.4 mIU/mL
3 - 11 Months: 0.0 - 1.2 mIU/mL
1 - 9 Years: 0.0 - 0.3 mIU/mL
10 - 12 Years: 0.0 - 4.3 mIU/mL
13 - 14 Years: 0.4 - 6.5 mIU/mL
15 - 16 Years: 0.0 - 13.1 mIU/mL
17 - 18 Years: 0.0 - 8.4 mIU/mL
Interpretive Data:
Normal Menstruating Females:
Follicular Phase: 1.8 - 11.8 mIU/mL
Mid-Cycle Peak: 7.6 - 89.1 mIU/mL
Luteal Cycle: 0.6 - 14.0 mIU/mL
Postmenopausal without Hormone Therapy: 5.16 - 61.99 mIU/mL

Male:
4 Days - 2 Months: 0.2 - 3.8 mIU/mL
3 - 1 Months: 0.0 - 2.9 mIU/mL
1 - 9 Years: 0.0 - 0.3 mIU/mL
10 - 12 Years: 0.0 - 4.3 mIU/mL
13 - 14 Years: 0.0 - 4.1 mIU/mL
15 - 16 Years: 0.8 - 4.8 mIU/mL
17 - 18 Years: 0.9 - 7.1 mIU/mL
>/= 19 Years: 0.6 - 12.1 mIU/mL
377
378
Magnesium
0 - 20 Years: 1.5 - 2.3 mg/dL
>/= 21 Years: 1.6 - 2.6 mg/dL
379
380
Malaria
Screan: Negative

% Parasitemia: 0 %
381
382
Meningitis/Enchephalitis Panel by PCR, CSF
Not Detected
383
384
Methicillin-resistant staphylococcus aureus (MRSA) PCR
Negative
385
386
Methotrexate Level
Interpretive Data:
Methotrexate serum levels depend on indication for use, dosage, mode of administration, treatment regimen, individual pharmacokinetics, metabolism and other clinical factors.

24 hr: 5-10 umol/L
48 hr: 0.5-1.0 umol/L
72 hr: <0.2 umol/L
387
388
Microalbumin, Urine
RANDOM:
< 30 mg/L

TIMED:
Output:
Reference: < 30 mg/24hr
Interpretive Data:
Normal: < 30 mg/24hr
Microalbuminuria: 30 - 299 mg/24hr
Macro clinical albuminuria: >/= 300 mg/24hr

Concentration:
Reference: < 20 ug/min
Interpretive Data:
Normal: < 20 ug/min
Microalbuminuria: 20 - 199 ug/min
Macro clinical albuminuria: >/= 200 ug/min
389
390
Microalbumin/Creatinine Ratio, Urine
< 30 mg/g

Interpretive Data:
Normal to Mildly Increased: < 30 mg/g
Moderately Increased: 30 - 299 mg/g
Severely Increased: >/= 300 mg/g

Two of three specimens of microalbumin/creatinine ratio should be abnormal before considering a patient to have high or very high albuminuria.
391
392
Monotest
Negative
393
394
Myeloperoxidase IgG (MPO) Antibody
< 3.5 U/mL

Interpretive Data:
< 3.5 Normal
3.5-5.0 Equivocal
> 5.0 Positive

The specificity of anti-MPO for systemic vasculitis and/or idiopathic crescentic glomerulonephritis is as high as 95% when groups of patients with renal disorders and diseases related to vasculitis are studied. However, MPO antibodies occur incidentally in other diseases such as drug induced lupus erythematosus, rheumatoid arthritis and inflammatory bowel disease.
395
396
Mycobacterium Tuberculosis by PCR
Not Detected
397
398
Mycoplasma pneumonia DNA
Not Detected
399
400
Myoglobin
Male: < 93 ng/mL
Female: < 81 ng/mL
401
402
Neisseria gonorrhoeae (GC), NAAT
Negative
403
404
Occult Blood, Fecal/Gastric/Vomitus
Negative
405
406
Osmolality
SERUM:
270 - 295 mOsm/kgH2O

URINE:
50 - 1200 mOsm/kgH2O

Interpretive Data:
Varies significantly with hydration
Average fluid intake 300 - 900
After 12 Hr fluid restriction > 850
407
408
Parathyroid Hormone (PTH), Intact
ABBOTT: (Midlands, Greenville Memorial, Oconee)
9 - 77 pg/mL

ROCHE: (Patewood Memorial)
15 - 72 pg/mL
409
410
Parathyroid Hormone (PTH) Intraoperative
Interpretive Data:
<50% of baseline value
This assay has not been clinically validated for intraoperative use, however intraoperative measurements were included in assay validations performed by Abbott.
411
412
Phenobarbital Therapeutic Range
15 - 40 ug/mL
413
414
Phosphorus
0 - 14 Days: 5.6 - 10.5 mg/dL
15 Days - 11 Months: 4.8 - 8.4 mg/dL
1 - 4 Years: 4.3 - 6.8 mg/dL
5 - 12 Years: 4.1 - 5.9 mg/dL
13 - 15 Years:
Male: 3.5 - 6.2 mg/dL
Female: 3.2 - 5.5 mg/dL
16 - 18 Years: 2.9 - 5.0 mg/dL
>/=19 Years: 2.3 - 4.7 mg/dL
415
416
Pinworm Prep/Exam
Not Present
417
418
Platelet Function Screen (PFS)
ASPIRIN: 350 - 549 sec

P2Y12: 50 - 208 sec

SCREEN:
Col/Epi: 78 - 177 sec
Col/ADP: 50 – 102 sec
419
420
Post Vasectomy Semen Analysis
Post Vas Total Sperm: Absent
Post Vas Semen Volume: 0.5 - 5.0 mL
Post Vas Nonmotile Sperm: < 1%
Post Vas Motile Sperm: < 1%
421
422
Potassium (K+)
SERUM/PLASMA:
0 - 27 Days: 3.7 - 5.9 mmol/L
28 Days - 1 Year: 4.1 - 5.3 mmol/L
2 - 17 Years: 3.4 - 4.7 mmol/L
>/= 18 Years: 3.5 - 5.1 mmol/L

URINE:
Random:
Interpretive Data: No Reference Ranges Established

Timed:
25.0 - 125.0 mmol/24 hr
Interpretive Data: Varies significantly with hydration and diet.
423
424
Prealbumin
0 - 11 Months: 7.0 - 25.0 mg/dL
1 - 11 Years: 11 - 34.0 mg/dL
>/= 12 Years: 14.0 - 45.0 mg/dL
425
426
Procalcitonin
< 0.10 ng/mL

Interpretive Data:
< 0.5: On the first day of ICU admission is associated with a low risk for progression to severe sepsis and/or septic shock
> 2.0: On the first day of ICU admission is associated with a high risk for progression to severe sepsis and/or septic shock

Procalcitonin values are physiologically increased in neonates during the first two Days of life. The reference range applies from three Days after birth.
427
428
Progesterone
Male: < 0.3 ng/mL

Normal Menstruating Females:
Follicular Phase: < 0.4 ng/mL
Luteal Phase: 1.2 - 15.9 ng/mL

Postmenopausal Females: <0.3 ng/mL

Pregnant Females:
First Trimester: 2.8 - 147.3 ng/mL
Second Trimester: 22.5 - 95.3 ng/mL
Third Trimester: 27.9 - 242.5 ng/mL
429
430
Prolactin
4 - 29 Days: 12.6 - 213.0 ng/mL
30 Days - 11 Months: 6.3 - 114.0 ng/mL
1 - 18 Years: 4.2 - 23.0 ng/mL
>/= 19 Years:
Male: 3.5 - 19.4 ng/mL
Female: 5.2 - 26.5 ng/mL
431
432
Protein C Activity
70 - 161 %
433
434
Protein S Activity
70 - 140 %
435
436
Protein, Total
SERUM:
0 - 14 Days: 5.3 - 8.3 g/dL
15 Days - 11 Months: 4.4 - 7.1 g/dL
1 - 5 Years: 6.1 - 7.5 g/dL
6 - 8 Years: 6.4 - 7.7 g/dL
9 - 18 Years: 6.5 - 8.1 g/dL
>/= 19 Years: 6.2 - 8.3 g/dL

URINE:
Random: 10 - 140 mg/L

Timed: < 300 mg/24 hr
At Rest 50 - 80 mg/24 hr

BODY FLUID:
Interpretive Data: Pleural and Pericardial: Transudate effusions have a low concentration of Total Protein. Exudate effusions have a high concentration of Total Protein. Serous fluid Total Protein values >/=3.0 g/dL separate exudates from transudates. A ratio of serous fluid total protein to a simultaneously collected serum protein of >/=0.5 is predictive of an exudate.

CSF:
0 - 30 Days: 20.0 - 80.0 mg/dL
>/= 1 Month: 15.0 - 45.0 mg/dL
437
438
Protein/Creatinine Ratio, Urine
< 0.2 mg/mg
439
440
Protein Electrophoresis, Blood
Albumin: 3.00 - 5.05 g/dL
Alpha 1 Globulin: 0.13 - 0.36 g/dL
Alpha 2 Globulin: 0.57 - 1.22 g/dL
Beta: 0.69 - 1.33 g/dL
Gamma Globulin: 0.63 - 2.00 g/dL
Alb/Glob Ratio: 0.92 - 1.86
441
442
443
Prothrombin Time (PT)/INR
PT: 11.9 - 14.3 seconds

INR: 0.8 - 1.2
444
445
PT Mixing Study
No Inhibitor Detected
446
447
Partial Thromboplastin Time (PTT)
24 - 36 seconds
448
449
PTT Mixing Study
No Inhibitor Detected
450
451
PSA
TOTAL: < 4.1 ng/mL

FREE: > 2.5 ng/mL

% FREE: > 27 %
452
453
Quantiferon TB Plus
Negative
454
455
-Respiratory Panel by PCR
.
456
Adenovirus
Not Detected
457
Bordetella Pertussis
Not Detected
458
Bordetella Parapertussis
Not Detected
459
Chlamydophilia Pneumoniae
Not Detected
460
Coronavirus 229E
Not Detected
461
Coronavirus HKU1
Not Detected
462
Coronavirus NL63
Not Detected
463
Coronavirus OC43
Not Detected
464
Coronavirus SARS-CoV-2
Not Detected
465
Human Metapneumovirus
Not Detected
466
Human Resp Syncytial Virus
Not Detected
467
Influenza Virus A
Not Detected
468
Influenza A/H1 2009
Not Detected
469
Influenza A/H1
Not Detected
470
Influenza A/H3
Not Detected
471
Influenza Virus B
Not Detected
472
Mycoplasma Pneumoniae
Not Detected
473
Parainfluenza Virus 1
Not Detected
474
Parainfluenza Virus 2
Not Detected
475
Parainfluenza Virus 3
Not Detected
476
Parainfluenza Virus 4
Not Detected
477
Rhino/Entero
Not Detected
478
479
Respiratory Syncytial Virus (RSV) Antigen
Negative
480
481
Reticulocyte Count (Automated)
RELATIVE
0 - 3 Days: 3.47 - 5.40 %
4 - 30 Days: 1.06 - 2.37 %
31 - 60 Days: 2.12 - 3.47 %
61 Days - 5 Months: 1.55 - 2.70 %
6 Months - 1 Year: 0.99 - 1.82 %
2 - 5 Years: 0.82 - 1.45 %
6 - 11 Years: 0.98 - 1.94 %
12 - 17 Years: 0.90 - 1.49 %
>/= 18 Years:
Male: 0.51 - 1.81 %
Female: 0.50 - 1.70 %

ABSOLUTE
0 - 3 Days: 0.1475 - 0.2164 Mil/uL
4 - 30 Days: 0.0513 - 0.1104 Mil/uL
31 - 60 Days: 0.0518 - 0.0779 Mil/uL
61 Days - 5 Months: 0.0482 - 0.0882 Mil/uL
6 Months - 1 Year: 0.0435 - 0.1111 Mil/uL
2 - 5 Years: 0.0364 - 0.0680 Mil/uL
6 - 11 Years: 0.0424 - 0.0702 Mil/uL
12 - 17 Years: 0.0416 - 0.0651 Mil/uL
>/= 18 Years:
Male: 0.026 - 0.095 Mil/uL
Female: 0.164 - 0.0776 Mil/uL

IRF
1 - 3 Days: 30.5 - 35.1 %
4 - 30 Days: 14.5 - 24.6 %
31 - 60 Days: 19.1 - 28.9 %
2 - 5 Months: 13.4 - 23.3 %
6 - 23 Months: 11.4 - 25.8 %
2 - 5 Years: 8.4 - 21.7 %
6 - 11 Years: 8.9 - 24.1 %
12 - 17 Years: 9.0 - 18.7 %
>/= 18 Years:
Male: 9.3 - 17.4 %
Female: 2.3 - 13.4 %

HEMOGLOBIN EQUIVALENT
Male:
0 - 5 Months: 27.6 - 38.7 pg
6 - 23 Months: 28.7 - 35.7 pg
2 - 5 Years: 27.7 - 37.8 pg
6 - 11 Years: 32.4 - 37.6 pg
12 - 17 Years: 30.3 - 40.4 pg
>/= 18 Years: 36.0 - 38.6 pg
Female:
0 - 5 Months: 29.2 - 37.5 pg
6 - 23 Months: 30.1 - 35.7 pg
2 - 5 Years: 29.3 - 37.3 pg
6 - 11 Years: 30.4 - 39.7 pg
12 - 17 Years: 29.9 - 38.4 pg
>/= 18 Years: 30.6 - 40.7 pg
482
483
Rheumatoid Factor (RF)
< 30 IU/mL
484
485
Rotavirus Antigen
Negative
486
487
Strep Group A Screen
Negative
488
489
Salicylate
< 30 mg/dL
490
491
Serine Protease 3 (PR-3) Antibody
< 2.0 U/mL

Interpretive Data:
< 2.0 Normal
2.0-3.0 Equivocal
> 3.0 Positive

Anti-PR3 antibodies are highly specific for GPA. However, PR3 antibodies are reported in infective disorders in monoclonal gammopathy and in a few cases of malignancy without signs of secondary vasculitis.
492
493
Sex Hormone Binding Globulin (SHBG)
Male: 11.2 - 78.1 nmol/L
Female: 11.7 - 137.2 nmol/L
494
495
Sickle Cell Screen
Negative
496
497
Sirolimus
5.0 - 15.0 ng/mL
498
499
Sodium
SERUM:
0 - 26 Days: 133 - 146 mmol/L
27 - 1 Year: 139 - 146 mmol/L
2 - 17 Years: 138 - 145 mmol/L
>/= 18 Years 136 - 145 mmol/L

URINE:
Random: No reference ranges established.

Timed:
Male:
6 - 10 Years: 41 - 115 mmol/24hr
10 - 14 Years 63 - 177 mmol/24hr
>/= 14 Years: 40 - 220 mmol/24hr
Female:
6 - 10 Years: 20 - 69 mmol/24hr
10 - 14 Years 48 - 168 mmol/24hr
>/= 14 Years: 40 - 220 mmol/24hr

Interpretive Data: Varies significantly with hydration and diet.
500
501
Special Fungal/Pneumocystis Stain
Negative
502
503
Strep pneumoniae Antigen, Urine/CSF
Negative
504
505
-Syphilis Testing
.
506
Treponema Antibody
Non-Reactive
507
Rapid Plasma Reagin (RPR)
Non-Reactive
508
Treponema Particle Agglutination
Non-Reactive
509
VDRL, CSF
Non-Reactive
510
511
T3, Free
Male and Female:
4 Days - 11 Months: 2.32 - 4.87 pg/mL
1 - 11 Years: 2.79 - 4.42 pg/mL
12 - 14 Years:
Male: 2.89 - 4.33 pg/mL
Female: 2.50 - 3.95 pg/mL
15 - 18 Years:
Male: 2.25 - 3.85 pg/mL
Female: 2.31 - 3.71 pg/mL
>/= 19 Years: 1.71 - 3.71 pg/mL
512
513
T3, Total
4 Days - 11 Months: 85 - 234 ng/dL
1 - 11 Years: 113 - 189 ng/dL
12 - 14 Years: 98 - 176 ng/dL
15 - 16 Years: 93 - 156 ng/dL
17 - 18 Years: 90 -168 ng/dL
>/= 19 Years: 58 - 159 ng/dL
514
515
T4, Free
0 - 11 Months:
Male: 0.90-1.80 ng/dL
Female: 0.90-1.60 ng/dL
1 - 10 Years: 0.80-1.60 ng/dL
11 - 20 Years: 0.80-1.40 ng/dL
>/= 21 Years: 0.70-1.50 ng/dL
516
517
T4, Total
4.87 - 11.72 ug/dL
518
519
Tacrolimas (FK506)
5.0 - 20.0 ng/mL
520
521
-Thromboelastogram (TEG)
.
522
TEG, Basic
R Plain 5.0 - 10.0 min
K Plain 1.0 - 3.0 min
Angle Plain 53.0 - 72.0 deg
MA Plain 50.0 - 70.0 mm
LY30 Plain 0.0 - 8.0 %
R Heparin Treated 5.0 - 10.0 min
K Heparin Treated 1.0 - 3.0 min
Angle Heparin Treated 53.0 - 72.0 deg
MA Heparin Treated 50.0 - 70.0 mm
LY30 Heparin Treated 0.0 - 8.0 %
523
TEG, Accelerated
R Rapid Plain 0.4 - 0.7 min
K Rapid Plain 0.6 - 2.3 min
Angle Rapid Plain 64.0 - 80.0 deg
MA Rapid Plain 52.0 - 71.0 mm
LY30 Rapid Plain 0.0 - 8.0 %
TEG ACT Plain 86.0 - 118.0 sec
R Rapid Heparin Treated 0.4 - 0.7 min
K Rapid Heparin Treated 0.6 - 2.3 min
Angle Rapid Heparin Treated 64.0 - 80.0 deg
MA Rapid Heparin Treated 52.0 - 71.0 mm
LY30 Rapid Heparin Treated 0.0 - 8.0 %
TEG ACT Heparin Treated 86.0 - 118.0 sec
524
TEG with Platelet Mapping
R Plain 5.0 - 10.0 min
K Plain 1.0 - 3.0 min
Angle Plain 53.0 - 72.0 deg
MA Plain 50.0 - 70.0 mm
LY30 Plain 0.0 - 8.0 %
R Heparin Treated 5.0 - 10.0 min
K Heparin Treated 1.0 - 3.0 min
Angle Heparin Treated 53.0 - 72.0 deg
MA Heparin Treated 50.0 - 70.0 mm
LY30 Heparin Treated 0.0 - 8.0 %
525
526
Testosterone
Male:
21 - 49 Years: 240 - 871 ng/dL
>/= 50 Years: 221 - 716 ng/dL

Female:
Premenopausal 21 - 49 Years: 14 - 53 ng/dL
Postmenopausal >/= 50 Years: 12 - 36 ng/dL
527
528
Theophylline
5 - 20 ug/mL
529
530
Thrombin Clot Time
13.0 - 21.0 seconds
531
532
Thyroglobulin Antibody
< 4.1 IU/mL
533
534
Thyroid Peroxidase Autoantibodies (TPO)
< 5.6 IU/mL
535
536
Tissue Transglutaminase (TTG), IgA
< 7.0 EliA u/mL

Interpretive Data:
0.1-6.9: Negative
7.0-10.0: Equivocal
>1 0.0: Positive
537
538
Tobramycin
TROUGH:
0 - 2 Months < 1.1 ug/mL
>/= 3 Months < 2.0 ug/mL

PEAK:
5.0 - 10.0 ug/mL

RANDOM:
2.0 - 10.0 ug/mL
539
540
Toxoplasma IgG
Negative
541
542
Transferrin
0 - 62 Days: 104 - 224 mg/dL
63 Days - 11 Months: 107 - 324 mg/dL
1 - 59 Years:
Male: 174 - 364 mg/dL
Female: 180 - 382 mg/dL
>/= 60 Years:
Male:163 - 344 mg/dL
Female:173 - 360 mg/dL
543
544
Transferrin Saturation
Male: 20 - 50 %
Female: 15 - 50 %
545
546
Trichomonas Vaginalis, NAAT
Negative
547
548
Troponin
< 0.03 ng/mL
549
550
Thyroid Stimulating Hormone (TSH)
4 Days - 5 Months: 0.730 - 4.770 uIU/mL
6 Months - 13 Years: 0.700 - 4.170 uIU/mL
14 - 18 Years: 0.470 - 3.410 uIU/mL
>/= 19 Years: 0.350 - 4.940 uIU/mL
551
552
Total Volume, Urine
Varies significantly with hydration.

0 - 2 Days: 30-60 mL/24 hr
3 - 9 Days: 100-300 mL/24 hr
10 Days - 1 Month: 250-450 mL/24 hr
2 - 11 Months: 400-500 mL/24 hr
1 - 2 Years: 500-600 mL/24 hr
3 - 4 Years: 600-700 mL/24 hr
5 - 7 Years: 650-1000 mL/24 hr
8 - 14 Years: 800-1400 mL/24 hr
15 - 59 Years:
Male: 800-1800 mL/24 hr
Female: 600-1600 mL/24 hr
>/= 60 Years: 250-2400 mL/24 hr
553
554
Unfractionated Heparin Anti-Xa (UFH)
0.30 - 0.70 IU/mL
555
556
Urea Nitrogen
BLOOD (BUN):
Male:
0 - 14 Days: 3 - 22 mg/dL
15 Days - 11 Months: 4 - 17 mg/dL
1 - 9 Years: 9 - 22 mg/dL
10 - 18 Years: 7 - 20 mg/dL
19 - 49 Years: 9 - 21 mg/dL
>/= 50 Years: 8 - 26 mg/dL

Female:
0 - 14 Days: 3 - 22 mg/dL
15 Days - 11 Months: 4 - 17 mg/dL
1 - 9 Years: 9 - 22 mg/dL
>/= 10 Years: 7 - 20 mg/dL

URINE:
Random: No Reference Ranges Established

Timed:
3,000-5,000 mg/6 Hrs
12,000 - 20,000 mg/24 Hrs
557
558
Uric Acid
0 - 14 Days: 2.8 - 12.0 mg/dL
15 Days - 11 Months: 1.6 - 6.3 mg/dL
1 - 11 Years: 1.8 - 4.9 mg/dL
12 - 18 Years:
Male: 2.6 - 7.6 mg/dL
Female: 2.6 - 5.9 mg/dL
>/= 19 Years:
Male: 3.5 - 7.2 mg/dL
Female: 2.6 - 6.0 mg/dL
559
560
-Urinalysis
.
561
-Urinalysis Chem Screen
.
562
Appearance
Clear, Slightly Hazy, Hazy
563
Spec Gravity
1.003 - 1.035
564
Ph
4.6 - 8.0
565
Glucose
Negative
566
Protein
Negative
567
Ketone
Negative
568
Bilirubin
Negative
569
Blood
Negative
570
Nitrite
Negative
571
Urobilinogen
< 2.0 mg/dL
572
Leuk Esterase
Negative
573
-Urinalysis Microscopic Exam
.
574
WBC’s
0 - 5 /HPF
575
RBC’s
0 - 2 /HPF
576
Epithelial Cells (Squamous)
</= 8 /LPF
577
Renal Epithelial Cells
0 /LPF
578
Bacteria
< Moderate
579
Hyaline Casts
0 - 3 /LPF
580
Cast
0 /LPF
581
582
-Vaginitis Panel by PCR
.
583
Trichomonas
Negative
584
Gardnerella
Negative
585
Candida
Negative
586
587
Valproic Acid
TOTAL: 50 - 125 ug/mL

FREE: 6 - 22 ug/mL

FREE %: 5 - 18 %
588
589
Vancomycin
TROUGH:
10.0 - 20.0 ug/mL

PEAK:
30.0 - 50.0 ug/mL

RANDOM:
5.0 - 40.0 ug/mL
590
591
Varicella Zoster, IgM
Negative
592
593
Vitamin B12
213 - 816 pg/mL
594
595
Vitamin D 25-Hydroxy
30 - 100 ng/mL

Interpretive Data:
< 20: Deficiency
20-29: Insufficiency
30-100: Sufficiency
> 150: Possible Toxicity
596
597
Wet Prep (Manual)
None Seen/Not Present